Progressive Interstitial Renal Fibrosis Due to Chinese Herbs in a Patient with Calcinosis Raynaud Esophageal Sclerodactyly Telangiectasia (CREST) Syndrome

Emi Nishimagi, Yasushi Kawaguchi, Chihiro Terai, Hiroshi Kajiyama, Masako Hara and Naoyuki Kamatani

Abstract

A 58-year-old woman with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome presented with slowly progressive renal dysfunction. She was normotensive with normal plasma renin activity and lacking symptoms of vasculitis. Mild proteinuria was of tubular origin, but serological tests and an absence of sicca symptoms excluded the possibility of Sjogren’s syndrome. Light microscopic study of renal biopsy showed interstitial fibrosis with ectasia and degeneration of proximal tubule and lymphocyte infiltration. There were no remarkable changes in the glomeruli. Chromatographic analysis of the Chinese herbs regimen that she had been taking for several years demonstrated aristolochic acid. She was diagnosed as Chinese herbs nephropathy. Therapy with oral prednisolone was markedly effective in improving renal function and anemia. To our knowledge, this is the first report of Chinese herbs nephropathy complicating connective tissue disease. It is important to consider the possibility of Chinese herbs nephropathy when patients treated with Chinese herbs develop renal dysfunction.

Case Report

A 58-year-old woman with scleroderma was admitted to Aoyama Hospital, Tokyo Women’s Medical University because of dyspnea on effort and renal dysfunction. She had noticed Raynaud’s phenomenon at the age of 40. In 1985, she had started taking several kinds of Chinese herbs which were obtained from a pharmacy for edema of her hands and fingers. In 1986, she began attending an out-patient clinic for Chinese herbal medicine. While she continued to go to the clinic until 1999, the herbal formula was changed several times. She consulted our hospital in 1993 at 51 years of age, because of dyspnea on effort and palpitation. She was diagnosed as CREST syndrome, due to calcinosis of her finger tips, Raynaud’s phenomenon, esophageal reflux, sclerodactylia, telangiectasia, and positive anti-centromere antibody. She had normal renal function from her first examination until June 1997, then serum creatinine levels started to increase gradually.

On admission in 1999, physical examination revealed a 58 kg woman with blood pressure of 140/78 mmHg, and pulse rate 83/min. She had ankyloglossia, tongue-tie, telangiectasia of the chest and shoulders, sclerodactyly, nail fold thrombi, and calcinosis of her fingers and toes. She was afebrile and there was no edema. Urinalysis did not show albuminuria or hematuria. Investigations showed a hemoglobin of 10.9 g/dl with a normal white blood cell and platelet count. Blood chemistries revealed blood urea nitrogen 24 mg/dl, creatinine 2.1...
mg/dl, total protein 7.6 g/dl, AST 23 IU/l, ALT 22 IU/l, LDH 278 IU/l, glucose 115 mg/dl, sodium 142 mEq/l, potassium 4.0 mEq/l, chloride 107 mEq/l. Antinuclear antibody (1,280×, homogeneous and discrete-speckled pattern) and anti-centromere antibody (147 IU/ml, determined by enzyme immunoassay) were positive. The other autoantibodies including antitopoisomerase I, anti-SSA, anti-SSB, anti-RNP and anti-Sm antibodies were negative. Schirmer and gum tests were negative. The patient was evaluated as not having the complication of Sjögren’s syndrome. Plasma renin activity and angiotensin II were normal at 1.5 ng/ml/h and 24 mg/dl, respectively. Urine volume was 1,900 ml/day and 24-hour creatinine clearance was 22 ml/min. A 24-hour urine collection contained 450 mg of protein despite a negative albustix test, thereby suggesting that proteinuria was derived from tubular damage. Urinary β2 microglobulin was 16,746 μg/l (normal range: <200), and NAG was 6.1 U/l (normal range: ≤11.5). Ultrasonography revealed mildly atrophic kidneys. Renal biopsy contained a total of 13 glomeruli, of which 3 were totally sclerosed but other glomeruli were normal. In the interstitium, ectasia and degeneration of the proximal tubular cells and severe fibrotic changes with lymphocyte infiltration were seen focally (Fig. 1). There was no evidence of vascular involvement suggesting angiitis or scleroderma renal crisis (SRC). Immuno-fluorescence staining was negative.

Considering the prolonged clinical course and the laboratory and pathological findings, it was unlikely that SRC or angiitis was the cause of renal dysfunction. These results prompted us to assess the medicines this patient took as a cause of interstitial renal failure. After reviewing all the medicines she took, Chinese herbs were strongly suspected as the cause of renal failure. Recently, it has been reported that interstitial renal failure is induced by aristolochic acid contained in Chinese herbs. Since she had been taking a mixture of several Chinese herbs included in a single formula, we analyzed this Chinese herbs mixture. AA-I which is known to be one of the causative agents

Figure 1. Light microscopic observation of renal biopsy specimen (A) Glomeruli were normal. (Masson’s staining, ×200). (B) Ectasia and degeneration of the proximal tubular cells and severe fibrotic changes with lymphocyte infiltration were seen in the interstitium. (Masson’s staining, ×200). (C) There was no thickening or degeneration of the intima or media of arterioles. There was no thrombus in the vascular regions (Elastica-Van Gieson’s staining, ×100).
Chinese Herbs Nephropathy with CREST

Figure 2. HPLC trace of Chinese herbal formula. (A) Analysis of aristolochic acid I (AA-I). (B) Analysis of Chinese herbal formula taken in this case. Trace shows presence of AA-I in Chinese herbal formula.

of CHN was detected by HPLC (Fig. 2). Renal dysfunction and anemia had progressed gradually since February 1997, and continued to progress even after discontinuing all of the herbal medicines in September 1999. In the clinical course shown in Fig. 3, renal function and anemia had deteriorated further (creatinine: 2.1 mg/dl, Hb: 10.1 mg/dl) in February 2000. Blood pressure in this case was stable throughout the observation. The administration of oral prednisolone (30 mg/day) was started in March to treat CHN. The patient responded to steroid therapy and symptoms were improved (creatinine 1.4 mg/dl, Hb 12.5 g/dl).

Discussion

Renal dysfunction in the present case was diagnosed as CHN by renal histology and the presence of AA-I in the Chinese herbs the patient took. In general, the pathological examination of CHN is reported to reveal diffuse interstitial hypocellular fibrosis and tubular atrophy without any prominent glomerular disorder (1), which are similar findings to those of our case. AA detected in the Chinese herbs formula is reported to be a causative agent of renal interstitial fibrosis (2). AA is usually contained in the Chinese herb “Kanmokutsu”. The present patient received “Toki-shigyaku-ka-gosyuu-syokyo-to”, one of the traditional prescriptions of herbal mixtures. In Japan, the prescription contains “Mokutsu”, which is Akebia quinata in Latin, and usually does not contain AAs. However, when “Toki-shigyaku-ka-gosyuu-syokyo-to” is prepared in China, it often contains “Kanmokutsu” (aristolochia manshuriensis) in place of “Mokutsu” and this herb contains AAs (5). In the present case, the patient’s family doctor imported the Chinese herbs directly from China. We considered that “Kanmokutsu” might have been included in the “Toki-shigyaku-ka-gosyuu-syokyo-to” mixture made in China.

In AAs, nine analogs from plants are well known. These are I (A), II, III, IV, C (III a), D (IV a) and E (6). AA-I in particular is reported to be a potent cause of gene mutation (6), suggesting that the genotoxic activity would play a crucial role in the
pathogenesis of CHN.

Most reported patients with CHN show rapid deterioration of renal function despite discontinuation of the herbal medications. Schmeiser and colleagues demonstrated the presence of AA-derived DNA adducts in the renal tissue of patients with CHN (7) and suggested that DNA mutation was responsible for the renal fibrotic process and urothelial cancers observed in CHN (3). In the present case renal function showed progressive deterioration despite discontinuation of the herbal treatment as is typical of most patients with CHN. We suggested that mutations in the DNA level might be the reason why the progressive fibrotic changes persisted even though the exposure to AAs had stopped.

Carcinomas of the urinary tract are described in CHN with increasing frequency (8). Cosyns and colleagues studied nineteen kidneys and ureters from 10 CHN patients and demonstrated an overexpression of mutated p53 (a tumor suppressor gene) in all carcinoma in situ and papillary transitional cell carcinoma specimens examined (9). There was no evidence of such malignancy in this case at the time of the study. However, it is important to be aware of this evidence and strict observation must be continued.

The standard treatment of CHN has not yet been established. In the present case, oral prednisolone was given and her renal function and anemia showed improvement. Vanherweghem and colleagues reported the efficacy of corticosteroid therapy in

<table>
<thead>
<tr>
<th>Reporters</th>
<th>Published year</th>
<th>Number of cases</th>
<th>Materials causing CHN</th>
<th>Therapy</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanherweghem et al</td>
<td>1993</td>
<td>35</td>
<td>Aristolochic acid</td>
<td>C-23 cases</td>
<td>HD-16 cases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CS-12 cases</td>
<td>HD-2 cases</td>
</tr>
<tr>
<td>Tanaka et al</td>
<td>1997</td>
<td>1</td>
<td>Aristolochic acid</td>
<td>C-1 case</td>
<td></td>
</tr>
<tr>
<td>Yang et al</td>
<td>2000</td>
<td>12</td>
<td>no analysis of herbal medication</td>
<td>C-12 cases</td>
<td>HD-7 cases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vanherweghem et al</td>
<td>2000</td>
<td>2</td>
<td>Aristolochic acid</td>
<td>C-2 cases</td>
<td></td>
</tr>
</tbody>
</table>

C: Cessation of herbal medications, CS: Corticosteroids, HD: Hemodialysis.
1996 (10). They compared a steroid-treated group (n=12) to a control group (n=23). Renal function was better preserved in the steroid-treated group at one year (p=0.001). Only two of the 12 patients in the steroid-treated group required dialysis at one year compared with 16 of 23 patients in the control group. Therefore, Vanherweghem and colleagues suggested that steroid induces interference with T lymphocyte functions and the synthesis of chemical mediators might lead to suppression of production and proliferation of the extracellular matrix as a possible mechanism. They gave prednisolone at a dose of 1 mg/kg weight as an initial dose. Since our case was complicated by CREST syndrome, high-dose steroid therapy was considered a risk factor for scleroderma renal crisis. Therefore, we decided to administer 30 mg/day which was much less than the dose used in the previous study. The effective dosage of prednisolone for patients with CHN has not yet been established. Comparisons of therapy and prognosis of several reports are shown in Table 1. To our knowledge, there were few reports of successful treatment of CHN that improved the prognosis. In this report, we demonstrated that the administration of corticosteroids may have improved the renal function of this CHN case, suggesting that steroid-therapy would be a good strategy for CHN. Further investigation of the treatment including corticosteroids for CHN must be undertaken in the future.

In this case, a diuretic Chinese herbal formula was prescribed for the edematous phase of skin thickening in CREST syndrome. In some cases of connective tissue diseases, especially slowly progressive cases, it is difficult to diagnose the disease from early symptoms. In fact, it is not rare for patients with connective tissue diseases taking Chinese herbal medications or some kinds of herbal tea since Chinese herbs are thought to be safe, and to have a lower incidence of adverse effects. The present case should serve to warn physicians of the importance of considering Chinese herbs as one of the possible causal factors promoting renal failure in patients with connective tissue diseases.

**Acknowledgement:** The authors appreciate Dr. Masahiko Watanabe (Tsumura Co.) for HPLC analysis of aristolochic acid.

**References**